/PRNewswire/ Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies,.
/PRNewswire/ Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies,.
Share this article
Share this article
NORTHBROOK, Ill. and BOSTON, Feb. 4, 2021 /PRNewswire/ Astellas announced the expansion of its Top Management to include two new positions today, both of which will report directly to Chief Executive Officer Kenji Yasukawa and serve as part of Astellas global executive committee:
Astellas US President
Percival Barretto-Ko was promoted to Chief Business Officer, focused on leading the company s new corporate strategic plan and enhancing Astellas external and internal innovation.
Astellas Institute for Regenerative Medicine President
Yoshitsugu Shitaka was promoted to Chief Scientific Officer, with responsibility for operations and the expansion of Astellas drug discovery research program platforms. He will also serve as Astellas President of its Drug Discovery Research (DDR) organization.